Fundraising FoxMODULATION THERAPEUTICS, INC.
Morgantown, US · 1 known investors
Find your way into MODULATION THERAPEUTICS, INC.
Sign up to see every warm intro you have to MODULATION THERAPEUTICS, INC.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MODULATION THERAPEUTICS, INC. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Modulation Therapeutics discovers and develops novel drug candidates targeting aggressive cancers and liver disease using peptide-based, small molecule, and targeted radio-therapy approaches. Founded in 2011 as a spinoff of Moffitt Cancer Center and now based in Morgantown, West Virginia, the company aims to advance three first-in-class therapies for nine disease indications through FDA approval.
Founders & leadership
Investors · 1
Non-dilutive funding · 17 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $344.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $400K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $258.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $248.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2017 | $284K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $242.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $279K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $244.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $288.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $218.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $156.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does MODULATION THERAPEUTICS, INC. do?
- Modulation Therapeutics discovers and develops novel drug candidates targeting aggressive cancers and liver disease using peptide-based, small molecule, and targeted radio-therapy approaches. Founded in 2011 as a spinoff of Moffitt Cancer Center and now based in Morgantown, West Virginia, the company aims to advance three first-in-class therapies for nine disease indications through FDA approval.
- Who founded MODULATION THERAPEUTICS, INC.?
- MODULATION THERAPEUTICS, INC. was founded by Lori Hazlehurst, Mark McLaughlin.
- Who are MODULATION THERAPEUTICS, INC.'s investors?
- MODULATION THERAPEUTICS, INC.'s investors include Florida Technology Seed Capital Fund.
- Where is MODULATION THERAPEUTICS, INC. headquartered?
- MODULATION THERAPEUTICS, INC. is headquartered in Morgantown, US.